Vividion publishes Phase 1 clinical data for VVD-214 in Nature Medicine

The company said the peer-reviewed study showed encouraging antitumor activity and a manageable safety profile in patients with MSI-high and/or dMMR solid tumors. In colorectal cancer, VVD-214 showed an 80.5% disease control rate and median progression-free survival of 7.3 months.